Study ID: CHDM201A2101

Study Title: A Phase I/II multi-center study of HDM201 added to chemotherapy in adult subjects with relapsed/refractory (R/R) or newly diagnosed acute myeloid leukemia (AML)

EudraCT Number: 2018-003107-19

ClinicalTrials.gov number: NCT03760445

Reason why study was not conducted (prematurely ended):

The Global team, in consultation with our management, decided on 30-Sep-2019, to close study CHDM201A2101. This decision was taken after careful consideration of multiple strategic factors. The treatment landscape in AML is changing rapidly; given this changing landscape and the projected timelines for completing our study, the current design may not be optimal. Idasanutlin, our key competitor, will report pivotal data during the first half of 2020; these data may help inform a new and better study design.

The decision to close CHDM201A2101 was not based on any known or new safety signals. As indicated above, the decision to close CHDM201A2101 will not stop development of HDM201 in the indication of AML or other indications such as myelofibrosis.